Skip to main content

Table 2 Numbers of major adverse events of the indicated grade (total 26 cycles)

From: A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis

 

Grade 1/2

Grade 3/4

All grades

   
 

N

%

N

%

N

%

Hematological

      

Neutrophil count decreased

9

34.6

6

23.1

15

57.7

Lymphocyte count decreased

9

34.6

6

23.1

15

57.7

Anemia

13

50.0

0

0.0

13

50.0

Platelet count decreased

10

38.5

1

3.8

11

42.3

Non-hematological

      

Hypertension

14

53.8

0

0.0

14

53.8

ALT/AST increased

6

23.1

2

7.7

8

30.8

Headache

8

30.8

0

0.0

8

30.8

Hyponatremia

1

3.8

6

23.1

7

26.9

Proteinuria

7

26.9

0

0.0

7

26.9